Biology & Life Sciences

ExplainerNeurotherapeutics

New Class of 'Psychoplastogen' Drugs Boosts Neuroplasticity Without Hallucinogenic Effects, Promising New Era for Depression Treatment

Neuropharmacologists 40%Psychedelic Therapists 30%Patient Advocacy Groups 30%

6 sources · 9d ago

Chromosome Evolution

Massive Genomic Analysis Reveals 'Evolutionary Highways' Guiding Chromosome Change Across All Animal Life

7 sources · 13d ago

Paleoanthropology

Major Rewrite Proposed for Human Family Tree: Australopithecus and Paranthropus Should Be Classified as Homo

6 sources · 17d ago

Autoimmune Disease

Efgartigimod Phase 3 Trial Succeeds in Severe Autoimmune Myositis Subtype

7 sources · 21d ago

Blindspot

Important stories the mainstream barely covered

High-impact news with only 1–3 outlets covering it. These stories matter — they just didn't make the radar.

All blindspots →

health

Combination Weight-Loss Drug CagriSema Achieves 23% Body Weight Reduction in Phase 3 Trial

Novo Nordisk's experimental dual-action obesity drug CagriSema drove a 23% weight reduction over 84 weeks in a Phase 3 trial, though it narrowly missed demonstrating non-inferiority against Eli Lilly's tirzepatide.

Pharmaceutical Developers 35%Clinical Practitioners 35%Market Analysts 30%

Explore more topics

News & Politics World Business Finance Technology Artificial Intelligence Health Energy